Urologic Oncology-Seminars and Original Investigations

Papers
(The H4-Index of Urologic Oncology-Seminars and Original Investigations is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Festschrift essay to celebrate Dr. Michael Droller110
Cover 2 - Masthead59
Genetic variations related to the prostate cancer risk: A field synopsis and revaluation by Bayesian approaches of genome-wide association studies49
GROWTH OF VON HIPPEL-LINDAU (VHL)-ASSOCIATED RENAL TUMORS DURING PREGNANCY47
A QUALITATIVE EXPLORATION OF THE EXPERIENCE OF TRANSGENDER AND GENDER NONCONFORMING PATIENTS WITH GENITOURINARY AND GYNECOLOGIC MALIGNANCIES31
UTILITY OF C-REACTIVE PROTEIN LEVELS IN IMPROVING RISK STRATIFICATION IN METASTATIC RENAL CELL CARCINOMA31
Investigation of prognostic biomarkers in patients with urothelial carcinoma treated with platinum-based regimens30
Predictors of discharge to home following major surgery for urologic malignancies: Results from the national surgical quality improvement program29
APPLICATION OF THE STRATCANS CRITERIA TO THE MUSIC AS COHORT: A STEP TOWARDS RISK STRATIFIED ACTIVE SURVEILLANCE28
REAL-WORLD ANALYSES OF MACE AND MORTALITY RISK IN PATIENTS WITH PROSTATE CANCER AFTER INITIATION OF LHRH AGONISTS VS. GNRH ANTAGONIST28
PREVALENCE OF OCCULT UROLOGIC MALIGNANCIES IN PATIENTS UNDERGOING SCREENING FOR LUNG CANCER28
DECIPHER® GENOMIC CLASSIFIER SCORE ON INITIAL BIOPSY IS ASSOCIATED WITH PROGRESSION FORM ACTIVE SURVEILLANCE TO TREATMENT IN PROSTATE CANCER28
PREOPERATIVE RADICAL CYSTECTOMY ERAS SCREENING AND EDUCATION – PATIENT REPORTED OUTCOMES28
The role of enhanced recovery after surgery protocols in the development of acute kidney injury following radical cystectomy27
“Published abstracts from the 24th Annual Meeting of the Society of Urologic Oncology”27
Predictive factors associated with differential pathologic response to neoadjuvant chemohormonal therapy in high-risk localized prostate cancer27
Guideline discordant care in patients with metastatic germ cell tumors26
Cover 2 - Masthead25
Editorial Board24
Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study24
Safety and efficacy of intravesical Bacillus Calmette-Guerin instillation for superficial recurrence following bladder-sparing therapy of muscle invasive bladder cancer: A retrospective study23
Exploring prostate-specific antigen (PSA) Testing rates and screening disparities in the all of us dataset23
Radical prostatectomy readmissions: Causes, risk factors, national rates, & costs22
Extracellular vesicles in renal cell carcinoma: A review of the current landscape and future directions22
NON-MUSCLE INVASIVE RECURRENCE AND MANAGEMENT DURING SURVEILLANCE IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ACHIEVE CLINICAL COMPLETE RESPONSE TO NEOADJUVANT CHEMOTHERAPY22
0.788733959198